Get the Stockscreener App
101.84
1.52%
-1.57
After Hours:
101.84
Novartis Ag Adr stock is traded at $101.84, with a volume of 2.01M.
It is down -1.52% in the last 24 hours and up +3.51% over the past month.
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
See More
Previous Close:
$103.41
Open:
$102.66
24h Volume:
2.01M
Relative Volume:
1.53
Market Cap:
$203.61B
Revenue:
$49.94B
Net Income/Loss:
$17.60B
P/E Ratio:
11.94
EPS:
8.53
Net Cash Flow:
$12.51B
1W Performance:
+2.12%
1M Performance:
+3.51%
6M Performance:
-7.69%
1Y Performance:
-4.96%
1-Day Range:
$101.75
$102.91
1-Week Range:
$98.12
$103.49
52-Week Range:
$92.35
$120.92
Novartis Ag Adr Stock (NVS) Company Profile
Name
Novartis Ag Adr
Sector
Industry
Phone
-
Address
-
Compare NVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
101.84 | 203.61B | 49.94B | 17.60B | 12.51B | 8.53 |
|
LLY
Lilly Eli Co
|
804.99 | 765.07B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
85.19 | 378.21B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
150.38 | 344.63B | 88.82B | 14.07B | 19.03B | 5.79 |
|
ABBV
Abbvie Inc
|
174.81 | 308.91B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
97.45 | 251.88B | 63.17B | 12.15B | 14.84B | 4.77 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Sep-11-24 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-05-24 | Downgrade | Goldman | Buy → Neutral |
| Sep-03-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-24 | Downgrade | Deutsche Bank | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-23-24 | Initiated | BMO Capital Markets | Market Perform |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-25-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-26-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-27-23 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-26-23 | Downgrade | Citigroup | Buy → Neutral |
| Dec-05-22 | Upgrade | Stifel | Hold → Buy |
| Sep-15-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| May-09-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-10-22 | Resumed | Citigroup | Buy |
| Dec-14-21 | Downgrade | Redburn | Buy → Neutral |
| Dec-06-21 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Dec-03-21 | Downgrade | Bryan Garnier | Buy → Neutral |
| Sep-20-21 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-22-21 | Initiated | Bernstein | Mkt Perform |
| Mar-10-21 | Downgrade | Argus | Buy → Hold |
| Feb-01-21 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Sep-10-20 | Upgrade | UBS | Neutral → Buy |
| Sep-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-15-20 | Upgrade | Citigroup | Neutral → Buy |
| Mar-10-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-25-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-25-19 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-10-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-02-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-11-18 | Resumed | Jefferies | Buy |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Sep-10-18 | Upgrade | BofA/Merrill | Underperform → Buy |
| May-29-18 | Downgrade | HSBC Securities | Buy → Hold |
| May-25-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jan-25-18 | Reiterated | Leerink Partners | Outperform |
| Dec-06-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jul-26-17 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jul-05-17 | Downgrade | Credit Suisse | Neutral → Underperform |
| Mar-09-17 | Initiated | Liberum | Buy |
View All
Novartis Ag Adr Stock (NVS) Latest News
Biological Drugs Strategic Research Report 2024-2030, Profiles of 45+ Players Including Abbott Laboratories, Amgen, Baxter, Biogen, BMS, Eli Lilly and Co, GSK, Merck, Novartis, and Pfizer - GlobeNewswire Inc.
Inari Medical Inc (NASDAQ: NARI): Getting A Free Pass? - Stocks Register
Metrics That Matter About Deutsche Bank AG (NYSE: DB) - Stocks Register
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
Saudi Arabia Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
South Korea Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
Thailand Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
The United States Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
The UAE Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
Weekly Upgrades and Downgrades - InvestorPlace
Communiqué de presse - GlobeNewswire Inc.
Are Investors Undervaluing Novartis (NVS) Right Now? - Yahoo Finance
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement for PLUVICTO™ - Barchart
Novartis: Time To Increase (NYSE:NVS) - Seeking Alpha
Glaucoma Therapeutics Strategic Industry Report 2024 - GlobeNewswire Inc.
5 high-yielding stocks that best reflect the UN’s Sustainable Development Goals - Equities News
Novartis Canada awards more than $680,000 to community-based programs aimed at advancing health equity - Barchart
5 High-Yielding Stocks Addressing the U.N. Sustainable Development Goals - Morningstar
Novartis Raises Sales Outlook For Mid-Term, Acquires Kate Therapeutics - Barchart
Addressing unmet needs for inherited neuromuscular diseases - Novartis
Inside the Market Dominance of the Top 10 Pharma Giants - Value the Markets
Canada Central Nervous System Therapeutic Market Size & Outlook, 2028 - Grand View Research
Thailand Antifungal Drugs Market Size & Outlook, 2023-2030 - Grand View Research
MEDIA STATEMENTNovartis Canada disappointed with outcome of pCPA negotiations for metastatic castration resistant prostate cancer treatment PLUVICTO™ - Barchart
Novo Nordisk A/S (NVO) Stock Price, News, Quote & History - Yahoo Finance
Our commitment to ethical and responsible use of Artificial Intelligence (AI) - Novartis
Novartis on Pace for Largest Percent Decrease Since March 2021 — Data Talk - Morningstar
Novartis Ag (NVS) Q3 2024 Earnings Call Transcript - Barchart
Gene Therapy - Novartis
Chemical Biology in Biomedical Research - Novartis
Radioligand therapy: delivering now, building for the future - Novartis
Novartis at ASH - Novartis
Novartis Beats on Q3 Earnings and Sales, Raises 2024 Outlook - Yahoo Finance
Novartis 2022 Financial Results - Novartis
Novartis Financial Results – Q2 2023 - Novartis
Novartis Ag Adr Stock (NVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):